Recruiting
Using a Blood Test to Monitor Metastatic Breast Cancer Treatment
The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.
ClinicalTrials.gov IDNCT05804578
PhaseNot Applicable
Enrollment150
SponsorDr. Christopher Mueller
Age18 Years
SexFEMALE
Conditions studied
Metastatic Breast Cancer
About this study
The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.
Primary outcomes
- Change in ctDNA level from baseline to 6 months of treatment (Baseline - 6 months)
- Changes in radiographic tumour assessments for monitoring response to treatment (3 months and 6 months)
- Change in measurable lytic lesions in participants with bone only metastasis assessed by CT scans as measured per RECIST v.1.1 (3 months and 6 months)
Eligibility information
Inclusion Criteria
-Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]
Study locations
- Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario, Kingston, Ontario K7L 5P9 Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-01.